📰 Medical News

Electroacupuncture for Post-Stroke Dysphagia: A New 30-Study Meta-Analysis Finds 29% Higher Effective Rate

July 4, 2026 · Frontiers in Neurology · TCM clinical evidence

A January 2026 meta-analysis pooled 30 RCTs and 2,290 stroke patients and found that electroacupuncture combined with conventional swallowing training produced a 29% relative increase in effective treatment rate. Dense-and-disperse waveforms outperformed continuous wave.

China's Bathhouse Boom Is the Public Face of a 120-Billion-Yuan TCM Wellness Industry — What International Patients Should Know

The Straits Times reported on 3 July 2026 that China's leisure bathhouse industry reached 120 billion yuan in 2025, up 10.5% year-on-year, with year-on-year growth exceeding 20% for four consecutive years. A $45 million Chinese-style bathhouse (House+ Bubble) opened in Singapore's Jurong East earlier in 2026; Beijing venues run 16-hour weekday passes from ~300 yuan with body-scrub, sauna, mahjong, and overnight stay; the Shui Guo chain has expanded from one Beijing outlet to nine branches in six cities. Behind the leisure story sits an integrated clinical wellness ecosystem that international patients can actually book into — hospital wellness departments (治未病, treating the undiseased) at TCM-affiliated tertiary hospitals such as Dongzhimen (BUCM), Yueyang (SHUTCM), and Guangdong Provincial Hospital of Chinese Medicine, plus Hainan Bo'ao Lecheng TCM access and 7-14 day hot-spring convalescence programs at Shimei Bay and Xinglong. The credential and regulatory setting differ across the three layers: vocational-trained cuozao technician for a leisure body-scrub, 5-year bachelor + 1-3 years specialty training for a clinical tuina or acupuncture session, and a Bo'ao Super Hospital attending for a coordinated TCM-Western care plan.

Electroacupuncture for Post-Stroke Dysphagia: A New 30-Study Meta-Analysis Finds 29% Higher Effective Rate

July 4, 2026 · Frontiers in Neurology · TCM clinical evidence

A January 2026 meta-analysis pooled 30 RCTs and 2,290 stroke patients and found that electroacupuncture combined with conventional swallowing training produced a 29% relative increase in effective treatment rate. Dense-and-disperse waveforms outperformed continuous wave.

AI-Powered TCM at Tianjin Da Ren Tang: How Zhang Boli's 180 Million Yuan Modernization Project Is Reshaping Traditional Chinese Medicine

China Daily reported on 3 July 2026 that Tianjin Pharmaceutical Da Ren Tang Group has launched a 180 million yuan (~US$25 million) AI-driven TCM modernization initiative led by Academician Zhang Boli (Chinese Academy of Engineering). The Tianjin Modern TCM New Quality Productive Forces Innovation Project replaces the ±10°C manual decoction margin of error with robotic temperature control at exactly 102°C, a 15% energy reduction, and improved alkaloid/flavonoid yield. A separate AI TCM diagnostic analyzer (tongue patterns + facial features via computer vision) produces a nine-type constitution report in seconds. Da Ren Tang chairwoman Wang Lei confirmed that more than 500 of the company's products have entered 47 countries as health supplements over the past 12 years. The 2026 NPC work report explicitly endorsed "promoting the inheritance and innovation of TCM and facilitating the integration of traditional Chinese and Western medicine" — the policy hook that gives the project state funding and hospital procurement support.

Acupuncture for IVF: Why the New Lancet Meta-Analysis Says “No Benefit” and a Same-Month Shanghai Meta-Analysis of 2,299 Women Says the Opposite

Two meta-analyses published within a week of each other in June 2026 reach opposite conclusions on acupuncture as an IVF add-on. The Lancet Obstetrics, Gynaecology & Women's Health meta-review of 85 trials (Lensen et al., University of Melbourne) found no evidence of benefit for acupuncture in the general IVF population, naming it among 7 add-ons without a detectable effect. A Frontiers in Endocrinology meta-analysis of 22 RCTs covering 2,299 women with PCOS undergoing IVF — led by Longhua Hospital, Shanghai University of Traditional Chinese Medicine, with Peking University Third Hospital as co-author institution — found a 13% absolute increase in clinical pregnancy rate, a 15% absolute increase in live birth rate, and a 633 IU reduction in total gonadotropin dose, all with p<0.00001. The contradiction is not a contradiction: the two papers are answering different questions about different patient populations, and the Chinese protocol (manual acupuncture, GnRH antagonist timing, 4 sessions around transfer) is the specific configuration that produces the 13-15% signal.

Hong Kong's CU Medicine Ranked World No. 2 in Gastroenterology & Hepatology — And Led The Lancet's First-Ever Liver Cancer Commission

The Chinese University of Hong Kong (CUHK) Faculty of Medicine has held a global top-three position in Gastroenterology & Hepatology for four consecutive U.S. News rankings editions, with the 2026-27 edition placing it at No. 2 worldwide and No. 1 in Asia. The same faculty led The Lancet's first-ever Commission on Liver Cancer — a 51-expert, multi-continent effort that is the journal's first major cancer report in its 200-year history spearheaded by Hong Kong scholars. CUHK is also the world's first testing ground for AI-powered upper-GI endoscopy, the birthplace of endoluminal robotics for GI cancer treatment, and the source of the first stool-microRNA colorectal cancer screening test. For international liver-cancer patients, the institution sits at the center of a clinical pipeline that is difficult to assemble outside East Asia.

China's Order 818: How 1,700 Hospitals Can Now Legally Charge Patients for Cell and Gene Therapies Without an NMPA Drug Approval — A Regulatory Pathway That Exists Nowhere Else

Order 818, in effect since May 1, 2026, lets roughly 1,700 top-tier (3A) hospitals in China clinically translate and charge patients for advanced therapeutics — cell therapy, gene therapy, gene editing — at the cellular or molecular level without first obtaining an NMPA drug registration. The order introduces a 1-to-5 year risk observation window before therapies can shift to the standard drug track, and pairs with a May 8, 2026 NHC consultation draft that would exclude most clinical data, imaging data, and protein data from human genetic resources export controls. For international patients whose home regulators have not approved a particular cell or gene therapy, Order 818 is the regulatory architecture that makes it available — at cost — at a 3A hospital in China. The pathway sits alongside the NMPA mass-market approval track, not in place of it, and is most relevant for autologous CAR-T, allogeneic iPSC-derived therapies, and rare-disease gene editing that will never justify a full BLA.

World's First Robotic Living-Donor Liver Transplant at Queen Mary Hospital: How 48 Robotic Microsurgery Procedures Are Rewriting the Limits of Precision Surgery in Hong Kong

HKUMed and Queen Mary Hospital have completed 48 robotic-assisted microsurgery procedures since June 2025, including the world's first robotic-assisted living-donor liver transplant in April 2026 and the first trans-hairline robotic microvascular head-and-neck reconstruction in late 2025. The platform combines tremor filtration, motion scaling, and seven-degrees-of-freedom micro-instruments to operate on vessels as fine as 0.1 mm — a level of precision that manual microsurgery cannot consistently reach. For international patients needing complex microvascular reconstruction, living-donor liver transplant, or super-microsurgical lymphaticovenous anastomosis for lymphoedema, the HKUMed program is the only one globally with this case volume and case mix as of mid-2026.

CMS's Silevimig Becomes World's First Bispecific Antibody for Rabies Passive Immunization After NMPA Approval

China Medical System Holdings (867.HK) received NMPA approval on June 22, 2026 for silevimig injection (GR1801), a recombinant fully human bispecific antibody that binds two epitopes on the rabies virus G protein (epitopes I and III). The product is the first bispecific antibody approved anywhere for rabies passive immunization, met non-inferiority vs HRIG in a Phase 3 adult trial, and is administered at the smallest dose volume of any RIG-class product. For travelers and expatriates in China who experience animal bites or scratches, the approval opens a new post-exposure prophylaxis option at major CMS-network hospitals in Beijing, Shanghai, and Guangzhou.

UCB's CEO: China Now Sources 1 in 4 of the World's New Drugs, and the "China for China" Mindset Is Over

UCB chief executive Jean-Christophe Tellier told China Daily in an interview published June 26, 2026 that China has moved from manufacturing to clinical-trial expertise and is now a source of drug discovery for the world. The remarks came with UCB's 30th anniversary in China and a June 4 agreement to build the UCB China Integrated Operation Centre in Suzhou Industrial Park. Tellier disclosed that 14 UCB global multi-centre clinical trials are running in China simultaneously, and noted that 19 of the innovative drugs approved by NMPA year-to-date 2026 came from Chinese manufacturers — out of 19 total. For international patients, the implication: China is structurally normal for both directions of medical flow.

UniXell's UX-DA003 iPSC Parkinson's Therapy Clears FDA IND, Completing China-US Dual Regulatory Track in Three Months

On June 23, 2026, the FDA cleared Shanghai-based UniXell Biotechnology's IND application for UX-DA003, an allogeneic iPSC-derived midbrain dopaminergic progenitor cell therapy for Parkinson's disease. Paired with NMPA's clearance on June 3, the candidate can now enter parallel Phase 1 trials in China and the US — the first Chinese iPSC Parkinson's program to clear both agencies off a shared iPSC seed cell bank with unified manufacturing. The dual-track approach uses the same cell line and the same differentiation protocol for both filings, a structural choice that matters for international patients evaluating where to enroll.

Mabwell's 6MW5311 LILRB4×CD3 Bispecific Antibody Cleared by NMPA for AML, CMML and Multiple Myeloma Trials

On June 24, 2026, Shanghai-based Mabwell (688062.SH, 02493.HK) received IND clearance from China's NMPA for 6MW5311, a LILRB4/CD3-targeting T Cell Engager bispecific with a "2+1" asymmetric structure and a steric hindrance safety design. The candidate is the first Chinese LILRB4 bispecific to clear an IND, and one of a small global set of TCE programs targeting acute myeloid leukemia, chronic myelomonocytic leukemia, and multiple myeloma — three indications where no T Cell Engager product is approved. AML alone accounts for 30,800 new cases per year in China (17.9% of the global total).

CARsgen's Satri-cel Approved by NMPA: World's First Solid-Tumor CAR-T Reaches Gastric Cancer Patients

On June 22, 2026, the National Medical Products Administration cleared satricabtagene autoleucel (satri-cel) — the world's first CAR-T therapy ever approved anywhere for a solid tumor. Indication: Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma after two prior lines of therapy. The Lancet Phase 2 trial behind the approval (CT041-ST-01, 3.25 vs 1.77 months PFS) was led by Prof Lin Shen at Peking University Cancer Hospital. For the 70% of gastric cancer patients who live in Asia — and the international patients who meet the biomarker profile — this is the first CAR-T available to them, and it is available first in China at an expected $120,000-$170,000 all-in cost.

Raffles Medical Group Treats 37,000 Foreign Patients in China in 2025 — Singapore's Hospital Operator Bets Big on Inbound Medical Tourism

On June 21, 2026, The Straits Times reported that Raffles Medical Group's three China hospitals in Beijing, Shanghai and Chongqing saw 37,000 international patients from 130 countries in 2025, up 7.9% year-on-year. Combined with Shanghai-based China Joyful Medical's 3x monthly enquiry growth (10→30-40) and New Zealand myeloma patient Emma Holden's CAR-T success in Shanghai, the institutional infrastructure for inbound medical tourism to China is moving from individual case studies to operator-scale growth.

Hengrui Pharma at ASCO 2026: 91 Studies, Four Phase III Readouts, and What It Means for Patients Coming to China

Jiangsu Hengrui Pharma presented 91 oncology studies at ASCO 2026 (Chicago, May 29-June 2), including 11 oral talks. We unpack four pivotal Phase III readouts: trastuzumab rezetecan in HER2+ colorectal cancer (HORIZON-CRC01, PFS 5.5 vs 2.8 months), camrelizumab + rivoceranib + TACE in unresectable HCC (CARES-336, PFS 11.1 vs 8.3 months), fluzoparib + abiraterone in mCRPC (FUZUPRO, rPFS 24.8 vs 19.9 months), and SHR-A2102 + adebrelimab in muscle-invasive bladder cancer (pCR 48.1%).

Akeso Ligufalimab (CD47) Plus AZA + VEN Cuts the Event-Free Survival Hazard by More Than Half in Frontline AML — EHA 2026 Phase II Readout

On June 13, 2026, at the EHA Congress in Milan, Akeso (9926.HK) presented oral Phase II data from the AK117-206 trial of its next-generation anti-CD47 antibody ligufalimab (AK117) added to azacitidine + venetoclax in older, treatment-naïve AML patients ineligible for intensive chemo. The triplet drove the event-free survival hazard ratio down to 0.46, with 9-month EFS of 53.2% versus 14.1% on AZA + VEN alone. We unpack the molecule, why CD47 has been hard, and how the data compares to the abandoned magrolimab program.

Akeso's HER3 ADC AK138D1 Plus Ivonescimab Enters First Patient in Phase Ib/II Breast Cancer Study: A Closer Look at the "IO2.0 + ADC2.0" Strategy (June 2026)

Akeso dosed the first patient in a Phase Ib/II trial pairing its HER3-targeted ADC AK138D1 with ivonescimab (PD-1/VEGF bispecific) in HER2-low/HER3-expressing metastatic breast cancer on June 15, 2026. The combination is positioned as a next-generation "IO2.0 + ADC2.0" pairing designed to beat the company's own ivonescimab + chemotherapy regimen in EGFR-mutant lung cancer. We cover the molecule design, the trial design, the breast cancer rationale, and what to watch at ASCO 2026 and ENA 2026 readouts.

Akeso Gumokimab (AK111) Approved by NMPA for Plaque Psoriasis: A New IL-17 Option From China With a Practical Dosing Schedule (June 2026)

Akeso's gumokimab (AK111), an internally-developed anti-IL-17 IgG1 monoclonal antibody, received NMPA approval on June 12, 2026 for moderate-to-severe plaque psoriasis. Phase III data showed 94.6% PASI 75 and 47.7% PASI 100 at Week 12, and 68.9% PASI 100 sustained through Week 52 — with only 17 subcutaneous injections per year. We cover the molecule, the trial results, what ankylosing spondylitis approval means, and what it costs international patients.

China's Nascent Medical Tourism Lures Foreign Patients with Cutting-Edge, Cheap Care — Bloomberg / Business Times (June 2026)

A 58-year-old New Zealand myeloma patient paid US$65,000 for a Shanghai CAR-T clinical trial that would have cost A$500,000 in Australia. Bloomberg's June 2026 dispatch frames China's medical tourism pivot around cost arbitrage, the seven approved CAR-T products matching the US, a May 2026 regulation shift banning clinical-research fees, and the Lecheng Hainan special zone. We unpack the patient story, the clinical picture, the price gap, the new oversight rules, and the skeptical case from analysts who say China is not yet Thailand.

Antengene ATG-201 CD19-CD3 Bispecific for Autoimmune Disease: NMPA Clears First Chinese Bispecific TCE Trial in Lupus, RA, and Vasculitis (June 2026)

Antengene's ATG-201 — a CD19 × CD3 bispecific T-cell engager with steric hindrance masking — received NMPA IND clearance on June 10, 2026 for the Phase I ATTRACT study in B-cell autoimmune diseases, to be run at Peking University People's Hospital under Prof. Zhanguo Li. UCB has worldwide rights after the FIH readout. We unpack the molecule, why masking matters, what the trial design looks like, and what it means for international patients with refractory lupus, vasculitis, and immune cytopenias.

Ori-C101 GPC3 CAR-T for Liver Cancer: NMPA Clears First Global Confirmatory Phase II Trial in HCC (June 2026)

Oricell Therapeutics' autologous GPC3 CAR-T therapy Ori-C101 — the first solid-tumor CAR-T in confirmatory Phase II anywhere in the world — was cleared by China's NMPA on June 8, 2026 for late-line advanced hepatocellular carcinoma. The Phase I BEACON study showed 66.7% ORR at the recommended Phase 2 dose and a 21.4-month median overall survival, more than double the historical 10.6-month benchmark. We unpack the science, the data, why this matters for international liver-cancer patients, and how the trial slots into Shanghai's emerging cell-therapy corridor.

5G Remote Surgery from Wuhan to Hyderabad: What Tongji Hospital Just Proved About Chinese Medical Technology

A 90-minute robot-assisted ureteral reimplantation was performed across 3,000 km by Dr. Syed Mohammed Ghouse at a console in Tongji Hospital — sub-200-millisecond latency over a commercial 5G core, with a Chinese-developed robot. The case is the first cross-border tele-surgery routed through a Chinese hospital's international office, and it points to a new model for medical service export.

Pakistani Patient's CAR-T Recovery in Shanghai (2026): What Jiahui International Cancer Center Did Differently

Muhammad, a 36-year-old Pakistani hospital worker with Stage IVB diffuse large B-cell lymphoma, achieved encouraging early recovery after personalized CAR-T therapy at Jiahui International Cancer Center in Shanghai. We unpack the case, the timeline, the cost of CAR-T in China vs the US, and what it tells us about cell therapy for international patients.

Russian Patients Flock to Heihe for AI-Powered Dental Work: Inside China's New Border-City Medical Tourism Wave (2026)

Hainan Boao Lecheng Medical Tourism (2026): China's Only Cross-Border Care Zone Opens One-Stop Hub for International Patients

Boao Lecheng in Hainan launched a one-stop services center in May 2026. The zone hosted nearly 10,000 overseas medical trips in 2025 and is the only place in mainland China with 570 foreign-approved drugs and devices available — including boron neutron capture therapy for cancer. Full guide for international patients.

BCI Neural Implant in China (2026): China's First Fully Implantable Brain-Computer Interface Trial Begins — What Paralysis Patients Need to Know

China launched its first multi-center trial for a fully implantable BCI in May 2026. The NMPA approved the world's first commercial BCI device in March. Treatment costs $40,000–$80,000 vs $100,000–$150,000 in the US.

Immunotherapy Treatment in China (2026): China Approves Drug That Beat Keytruda — What It Means for Patients

China's NMPA approved ivonescimab — a bispecific antibody that cut lung cancer progression by 49% vs pembrolizumab. Immunotherapy in China costs $2,800–$11,500 per cycle vs $30,000+ in the US.

FDA Approves Vepdegestrant (VEPPANU): The World's First PROTAC Cancer Drug — What It Means for Breast Cancer Patients Worldwide

On May 1, 2026, the FDA approved vepdegestrant (VEPPANU), the first-ever PROTAC protein degrader for ER+/HER2-/ESR1-muta...

Revolution Medicines' Daraxonrasib Gets FDA Green Light for Expanded Access — A New Option for Pancreatic Cancer Patients

The FDA has issued a 'safe to proceed' letter for daraxonrasib, allowing Revolution Medicines to offer its investigation...

CAR-T Therapy Cost in China (2026): NMPA Approves First Solid-Tumor CAR-T — What Patients Need to Know

CAR-T therapy in China costs $120,000–$170,000 — 60–70% less than the US. NMPA just approved the world's first CAR-T for...

CAR-T Therapy Cost in China (2026): BioOra Secures Rights to China-Made Atla-Cel — What Patients Need to Know

CAR-T therapy in China costs $40,000–$80,000 vs $500,000+ in the US. BioOra just licensed China's Atla-cel for global ma...

Thailand Mandates Tourist Health Insurance — What It Means for China Medical Tourism

Thailand now requires health insurance for all visitors as of 2026. How does this impact medical tourism to China? A pra...

Spine Surgery in China (2026): Robot-Assisted Procedure Cuts Incision from 20cm to 1cm — What Patients Need to Know | China Hospitals Guide

Shanghai surgeons now use robotic arms for spinal endoscopy, reducing incisions from 20cm to 1cm. Spine surgery in China...

Thailand Aims for 4.72M Chinese Visitors and $7.3B Medical Tourism Revenue — How Does China Compare?

Thailand just unveiled a major medical tourism push targeting 4.72M Chinese visitors and $7.3B in revenue by 2026. China...

Pancreatic Cancer Breakthrough: Drug Nearly Doubles Survival — How Does China Compare?

Revolution Medicines' KRAS inhibitor daraxonrasib cuts death risk by 40% in pancreatic cancer. mRNA vaccines enter phase...

South Korea's Medical Tourism Hits 2 Million Patients and $8.4B — How Does China Compare?

South Korea drew 2.01 million medical tourists in 2025, spending $8.4 billion. China is catching up with 410,000 inbound...

China's 24-Hour Spas Are Going Viral — And Rewriting the Rules of Wellness Tourism

Foreign tourists are skipping the Great Wall and filling 24-hour Chinese bathhouses instead. At roughly $50 for unlimite...

China's Inbound Medical Tourism Surge: 410K Patients in 2025, CAR-T and Oncology in the Lead

China received 410,000 inbound medical tourists in 2025, a 38% year-over-year surge. CAR-T therapy and advanced oncology...

Malaysia Launches First-Ever "Medical Tourism Year" — Can It Outcompete China?

Malaysia's MYMT 2026 campaign aims to position the country as Asia's top medical tourism destination. With 1.6 million h...

Hainan's Medical Tourism Zone Breaks Records: 865,000 Visitors in 2025 with 109% Growth

China's only medical tourism special zone in Hainan received 865,460 visitors in 2025, a 109% year-on-year surge. The Bo...

Doctors Sound Alarm: Overseas Cosmetic Surgery Risks Are 'Devastating' — Where Does China Fit In?

Over three million people travel abroad for cosmetic surgery each year, chasing lower prices. But doctors are now warnin...

Bali's New Medical Zone Is Quietly Rewriting the Rules of Asian Health Tourism

Indonesia's Sanur Health Special Economic Zone opened in June 2025 and is now targeting 140,000 patients annually. As Ba...

China Emerges as Global Medical Tourism Hub: CAR-T Therapy Leading the Way

China is becoming a top medical tourism destination. CAR-T cell therapy, cardiac surgery, and health checkups attract in...

Revolution Medicines' Daraxonrasib: A Breakthrough in Pancreatic Cancer — How Does China Compare?

Revolution Medicines' daraxonrasib cut pancreatic cancer death risk by 60% in a Phase 3 trial — the biggest breakthrough...

Pakistan's New Medical Tourism Push: A Fresh Challenger to Asia's Healthcare Hub Race

Pakistan has formally launched a national medical tourism initiative under the SIFC, aiming to become a regional hub for...

Thailand's New Tourist Health Insurance Mandate: How Does China Respond?

Thailand has announced mandatory health insurance for inbound tourists starting in 2026, joining a tightening trend acro...

Colombia's Antioquia Emerges as Latin America's Robotic Surgery Benchmark: How Does China Compare?

Colombia's Antioquia region has become a benchmark for robotic surgery in Latin America, according to a April 2026 repor...

Macao's Health Tourism Expands with New Hospitals and TCM Routes: How Does Mainland China Compare?

Macao unveiled major health tourism infrastructure at MITE 2026, including new hospitals from Peking Union Medical Colle...

Thailand's MedPark Hospital Courts Bangladeshi Patients: How Does China Compare?

Thailand's MedPark Hospital is ramping up next-generation medical care for Bangladeshi patients, as 60% of Bangladeshi t...

India's ISDE 2026 Breakthrough: Robotic Surgery & Organ-Preserving Care That Costs a Fraction of the West

India's ISDE 2026 conference in Hyderabad presented advanced esophageal cancer treatments, robotic esophagectomy, organ-...

US Proton Therapy Trial Shows 10% Survival Gain: How Does China Compare?

The NAPT 2026 conference revealed landmark Phase III trial data showing intensity-modulated proton therapy improved 5-ye...

Turkey's Hair Transplant Boom: How Does China Compare for Medical Tourism?

Turkey has become the world's hair transplant capital, attracting over 1 million medical tourists annually. We compare T...

Tanzania's Medical Tourism Push: How Does China Compare?

Tanzania's government announced fresh measures to promote medical tourism on April 8, 2026, targeting 3,000+ internation...

China's Inbound Medical Tourism Hits 1.28 Million Patients in 2025 — And the Growth Is Just Getting Started

China reported 1.28 million foreign patients in 2025, with the Boao Lecheng pilot zone seeing 109% year-on-year growth. ...

Vietnam Launches National Medical Tourism Alliance: How Does China Compare?

Vietnam's new Medical Tourism Alliance aims to keep patients at home and attract international visitors. We compare Viet...

China's Surgical Robot Revolution: How Chinese Hospitals Are Operating on Patients 10,000 km Away

As China's 93rd CMEF opens in Shanghai (April 9-12), West China Hospital's international remote surgery center has alrea...

UK Scientists Reveal New Blood Pressure Drug That Works When Others Fail: How Does China Compare?

A UCL-led Phase III trial reveals baxdrostat, a new aldosterone-blocking hypertension drug, cuts systolic blood pressure...

BPC-157 Peptide Therapy vs Statins: The Evidence Gap — How Does China Compare?

A growing number of US patients are choosing unproven peptide injections over statins backed by 170,000-participant tria...

Singapore's BAP1 Cancer Breakthrough: How Does China Compare?

Scientists in Singapore have uncovered a novel approach to treating aggressive BAP1-mutant cancers including mesotheliom...

US Explores Subscription Pricing for Twice-Yearly HIV Prevention Shot: How Does China Compare?

The US is piloting subscription-based pricing for lenacapavir, the twice-yearly injectable HIV prevention shot. With a l...

China's Space Hospital Research Takes Off: How Does It Compare to the US and Europe?

China has launched medical research satellites aimed at building the world's first space hospital, pushing the frontier ...

China International Medical Tourism Expo 2026: What to Expect

The China International Medical Tourism Expo returns to Shanghai in April 2026. Key industry players, hospital networks,...

Thailand's CAR-T Cell Therapy Breakthrough: How Does China Compare?

Thailand's Ramathibodi and Samitivej hospitals have joined forces to bring CAR-T cell therapy to leukemia and lymphoma p...

China's 9 Ministries Launch Medical Tourism Pilot Zones: What It Means for You

China's nine ministries jointly issued policies supporting international medical tourism. Pilot zones, visa extensions, ...

Egypt Emerges as Rising Star in Global Medical Tourism Market | ChinaHospitalsGuide

Egypt is rapidly becoming a major player in the global medical tourism industry, combining world-class healthcare with i...

AI Pharma Race: Insilico's $2.75B Eli Lilly Deal — How Does China Compare?

Insilico Medicine's $2.75B AI-driven drug discovery deal with Eli Lilly is the largest AI pharma deal in history. See ho...

Global Medical Tourism Boom: Turkey, Thailand, India Rise — Where Does China Stand?

Medical tourism is becoming a multi-billion dollar industry. Turkey just entered Newsweek's World's Best Hospitals for t...

India's Medical Tourism Boom: $13 Billion and Counting — How Does China Compare?

India's medical tourism market hits $13B in 2026 with 5 new government hubs. See how China compares in cost, quality, an...

GLP-1 Drugs Do More Than Weight Loss: What China Is Doing With Ozempic Alternatives

Research from March 2026 confirms GLP-1 drugs like Ozempic reduce heart and kidney risks beyond weight loss. See how Chi...

US T-Cell CAR-T Gets FDA Breakthrough: How Does China Compare?

Washington University's WU-CART-007 won FDA Breakthrough designation for T-cell leukemia March 2026. See how China's app...

CRISPR Upgrade for Cancer-Fighting Cells: How Does China Compare?

Researchers announce major CRISPR upgrade for CAR-T cell therapy. See how China's leading cancer hospitals compare in ac...

普通维生素或可治愈脂肪肝？中美治疗方案全面对比

2026年3月，美国研究证实一种常见维生素对脂肪肝疗效显著。本文对比中美脂肪肝治疗现状，揭示中国医院的独特优势。...

Japan-China Travel Strain: Japanese Patients from Northern Japan Increasingly Choose Chinese Hospitals

With Japan-China relations strained and flight routes reduced, growing numbers of Japanese patients from northern Japan ...

Trending Wellness Cities China 2026: Top TCM Tourism Destinations & Cost Guide

Discover China's top wellness destinations 2026 — Hainan, Beijing & Shanghai for TCM acupuncture, qigong & recovery. Com...

中国脑机接口获批：全球首例非侵入式设备入院，费用仅为Neuralink的1/5

2026年3月，中国脑机接口医疗器械全球首批获批上市，36例患者重获手部功能。本文对比中美脑机接口技术路线、费用与可及性。...

美国法院阻止疫苗政策变化：对中国儿童疫苗接种的启示

美国法官阻止RFK Jr.修改儿童疫苗接种计划。这一政策变化引发争议。中国在儿童疫苗接种方面有哪些经验可供借鉴？...

中国实体瘤CAR-T突破：57.1%有效率，费用仅为美国1/3

2026年2月中国实体瘤CAR-T疗法获突破，有效率达57.1%。本文对比中国与美国CAR-T疗法的技术、费用与可及性，揭示外籍患者为何选择来华就医。...

泰国康民国际医院全球百强蝉联六年，2026辅助生殖医疗旅游还有哪些新玩法

泰国康民国际医院连续六年蝉联泰国榜首，2026年试管婴儿医疗旅游持续升温。...

Singapore Becomes First Country to Achieve WHO's Highest Medical Device Certification: How Does China Compare?

Singapore is the first country globally to achieve WHO's highest maturity level for medical devices. We compare healthca...

Redirecting to Stem Cell Therapy in China Guide

...

日本质子治疗 vs 中国：8000例经验与技术普及的较量

日本质子治疗技术领先全球，筑波大学累计完成超8000例。中国质子治疗发展迅速，2026年多家新建医院即将开业。...

Stem Cell Therapy in China 2026: Costs, Clinics & Patient Guide

Explore China's leading stem cell therapy centers for diabetes, anti-aging & orthopedics. Compare costs, success rates &...

Deadly Hantavirus Outbreak on Cruise Ship MV Hondius: What You Need to Know About the Andes Virus Spreading Human-to-Human

A hantavirus outbreak on the cruise ship MV Hondius has killed 3 people and infected at least 8 passengers since April 2026. The Andes virus — confirmed by ECDC — is the only known hantavirus strain t

Stem Cell Therapy in China 2026: Costs, Clinics & Patient Guide

Explore China's leading stem cell therapy centers for diabetes, anti-aging & orthopedics. Compare costs, success rates & regulatory status at Hainan Boao Lecheng facilities. Free specialist matching.